In a 68-year-old man with hip osteoarthritis well controlled on celecoxib 200 mg daily who now has increased hip pain, is it appropriate to use diclofenac 2% gel for pain relief?

Recommend against using diclofenac gel and instead recommend following up with the primary care provider about an increase in celecoxib dosage to 200 mg twice daily.

The most appropriate recommendation is to avoid adding topical diclofenac gel while already on oral celecoxib and instead optimize the current systemic NSAID therapy by increasing celecoxib to 200 mg twice daily. This approach addresses inadequate pain control through dose escalation of the existing, well-tolerated COX-2 selective inhibitor rather than adding a second NSAID with potential for increased systemic absorption and adverse effects.

Rationale for Avoiding Concurrent NSAID Use

The critical issue here is avoiding concurrent use of multiple NSAIDs, which significantly increases gastrointestinal and cardiovascular risks without proportional benefit. While diclofenac 2% gel is marketed as having "minimal systemic absorption," this is misleading in clinical practice:

• Systemic absorption from topical diclofenac is substantial enough to cause clinically relevant drug interactions and adverse effects 1
• The EULAR guidelines explicitly document dose-dependent GI bleeding risk with diclofenac: OR = 2.2 for 75 mg/day, 3.2 for 75-150 mg/day, and 12.2 for >150 mg/day 1
• Combining oral and topical NSAIDs creates additive systemic NSAID exposure, increasing both GI perforation/ulcer/bleeding risk (RR 2.70-5.36) and cardiovascular events 1

Optimizing Celecoxib Dosing

The FDA label and clinical trials demonstrate that celecoxib can be safely escalated:

• Celecoxib 200 mg twice daily (400 mg/day total) is FDA-approved for osteoarthritis and provided significant pain reduction within 24-48 hours in OA flare studies 2
• Clinical trials show that 200 mg twice daily provided additional benefit for some patients beyond 100 mg twice daily, though 400 mg twice daily showed no further improvement 2
• The PRECISION trial demonstrated that celecoxib at doses up to 200 mg twice daily had comparable cardiovascular safety to naproxen and ibuprofen 2
• Celecoxib has significantly lower GI toxicity compared to non-selective NSAIDs like diclofenac (OR 0.18 for endoscopic ulcers) 1, 3

Why Not the Other Options?

Intra-articular corticosteroid injection: While the 2019 ACR/Arthritis Foundation guidelines conditionally recommend intra-articular corticosteroids for hip OA 4, and the 2025 AAOS guidelines support their use 5, this should be considered a second-line option after optimizing oral therapy. The patient's pain is recent-onset and represents inadequate dosing of current therapy rather than treatment failure. Additionally, hip injections require imaging guidance 4, adding complexity and cost.

Duloxetine: The ACR guidelines conditionally recommend duloxetine for hip OA 4, but this represents a different mechanism (centrally acting) rather than addressing inadequate anti-inflammatory therapy. Duloxetine has tolerability issues and side effects that make it less appropriate as a next step when the current NSAID therapy simply needs optimization. It should be reserved for patients who fail adequate NSAID therapy or have contraindications.

Topical diclofenac alone: While topical NSAIDs are recommended for knee and hand OA 6, 7, evidence for hip OA is limited. The deeper location of the hip joint makes topical penetration less reliable compared to superficial joints. More importantly, using it as monotherapy would mean discontinuing the celecoxib that was previously effective, which is illogical.

Clinical Algorithm

For this 68-year-old patient with breakthrough hip OA pain on celecoxib 200 mg daily:

1. Increase celecoxib to 200 mg twice daily (400 mg/day total) - this is within FDA-approved dosing and addresses inadequate pain control
2. Reassess in 1-2 weeks - celecoxib provides pain relief within 24-48 hours 2
3. If inadequate response after 2-4 weeks at optimized dose, then consider:
   • Intra-articular corticosteroid injection (with imaging guidance for hip)
   • Adding duloxetine if centrally-mediated pain component suspected
   • Evaluating for surgical referral if conservative measures fail

Important Caveats

• Monitor for cardiovascular and GI risk factors - at 68 years old, assess for hypertension, cardiovascular disease, history of GI bleeding, and concomitant antiplatelet/anticoagulant use
• Consider gastroprotection with PPI if GI risk factors present (age >65 is itself a risk factor) 1
• Avoid exceeding 400 mg/day celecoxib - doses of 400 mg twice daily showed no additional benefit 2
• Never combine multiple NSAIDs - the systemic absorption from topical formulations is sufficient to cause additive toxicity 1